Dr. Zhao Kun
Dr. Kun Zhao is the professor and Director of Division of Health Policy Evaluation and Technology Assessment in China National Health Development Research Center which is affiliated to Ministry of Health in China. Since 2007, Dr. Zhao plays the leading role in HTA development and training programs in China, and as principle investigators conducts a series of national HTA projects on cutting-edge devices, costly new drugs, immunotherapy and clinical procedures, such as DaVinci surgical robot related therapy, proton and heavy ion therapy, Cyberknife,Tomotherapy, Truebeam & Truebeam STX, Hepatitis B&C drugs, CIK immunotherapy, stem cell therapy, hemo and peritoneal dialysis for ESRD patients, HBV and HCV drug economic evaluation, HTA for secondary line of targeted drug for NSCLC. As PI, conducting several national evaluation projects such as the disease control priority setting in China for increasing by 1 year life expectancy, prioritization of maternal and children care program, the cost-effectiveness analysis of the vaccination preventing COPD from acute exacerbation, the study of HTA-based optimizing diagnosis and treatment pathways accompanying to provider payment reform in rural China. Also Dr Zhao is a member of ACE of Disease Control Priorities, Third Edition, ISPOR AP Chair (2018-2020), Asianet HTA Chair (2014-2016) and ISPOR HTA council committee member, HTAsiaLink board member and core author of university textbook of China HTA, and Program Evaluation. From 2009 to 2015, she got over 80 papers published in peer-review journals.
Session Panellist for: